Pediatric oncology group utilization of immunologic markers in the designation of acute lymphocytic leukemia subgroups: influence on treatment response.
The clinical application of blast cell immunophenotype testing is important in childhood ALL for the following reasons. (1) Knowledge of the immunologic group is important in predicting prognosis. Prognostic grouping may prove to be accomplished best by using a combination of traditional risk factors and immunologic phenotyping. However, definition of traditional risk factors may vary within the immunologic groups of ALL. (2) In assessing the relative effectiveness of different treatment regimens for children with ALL it is important to make comparisons among patients within the same major immunologic groups of ALL. (3) Identification of specific immunologic groups of patients within ALL may help in designing therapy for each group. The POG has already made preliminary attempts in this direction for T-ALL and B-ALL. However, leukemia species-specific therapy is still only a long-range goal. Laboratory research must endeavor to identify additional biologic characteristics peculiar to each major immunologic group of ALL. These characteristics may dictate therapeutic maneuvers in the future.
D000951:Antigens, Neoplasm / Q000032:analysis*; D001853:Bone Marrow / Q000276:immunology*; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D005260:Female; D000949:Histocompatibility Antigens Class II / Q000032:analysis; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000032:analysis; D007223:Infant; D007945:Leukemia, Lymphoid / Q000145:classification* / Q000276:immunology / Q000628:therapy; D008297:Male; D015260:Neprilysin; D011379:Prognosis
D000951:Antigens, Neoplasm; D000949:Histocompatibility Antigens Class II; D007140:Immunoglobulin Fab Fragments; D015260:Neprilysin